Immunotherapy in Pediatric Hematologic Malignant Neoplasms
Childhood acute leukemia has achieved tremendous treatment outcome improvement over the past several decades. Given that pediatric leukemia remains the most common type of childhood malignant tumors, there are still unmet needs in relapsed/refractory diseases. Moreover, reducing the toxic adverse ef...
Main Author: | Kyung Taek Hong |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Pediatric Hematology-Oncology
2020-04-01
|
Series: | Clinical Pediatric Hematology-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.15264/cpho.2020.27.1.14 |
Similar Items
-
Therapeutic Advances in Immunotherapies for Hematological Malignancies
by: Ayako Nogami, et al.
Published: (2022-09-01) -
Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies
by: Navdeep Jhita, et al.
Published: (2022-06-01) -
Immunotherapy of Multiple Myeloma: Promise and Challenges
by: Abramson HN
Published: (2021-09-01) -
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
by: Ji-Yoon Noh, et al.
Published: (2020-10-01) -
Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison
by: Rimas J Orentas, et al.
Published: (2014-06-01)